| Literature DB >> 27270163 |
Lauren Shih1, David Kaplan1, Larry W Kraiss2, T Charles Casper3, Robert C Pendleton1, Christopher L Peters4, Mark A Supiano5, Guy A Zimmerman1, Andrew S Weyrich1,6, Matthew T Rondina1,6,7.
Abstract
Emerging evidence implicates platelets as key mediators of venous thromboembolism (VTE). Nevertheless, the pathways by which platelets and circulating procoagulant proteins synergistically orchestrate VTE remain incompletely understood. We prospectively determined whether activated platelets and systemic procoagulant factors were associated with VTE in 32 older orthopedic surgery patients. Circulating platelet-monocyte aggregates (PMAs), p-selectin expression (P-SEL), and integrin αIIbβ3 activation (PAC-1 binding) were assessed pre-operatively and 24 hours post-operatively. The proinflammatory and procoagulant molecule C-reactive protein (CRP), which induces PMA formation in vitro, along with plasma d-dimer and fibrinogen levels were also measured. The primary outcome was VTE occurring within 30 days post-operatively. Overall, 40.6% of patients developed VTE. Patients with VTE had a significant increase in circulating PMAs and CRP post-operatively, compared to those without VTE. Changes in PMA and CRP in VTE patients were significantly correlated (r(2) = 0.536, p = 0.004). In contrast, P-SEL expression and PAC-1 binding, fibrinogen levels, and d-dimers were not associated with VTE. This is the first study to identify that increased circulating PMAs and CRP levels are early markers associated with post-surgical VTE. Our findings also provide new clinical evidence supporting the interplay between PMAs and CRP in patients with VTE.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27270163 PMCID: PMC4895334 DOI: 10.1038/srep27478
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of the study cohort and comparisons between patients with and without venous thromboembolism (VTE).
| Overall (n = 32) | No VTE (n = 19) | VTE (n = 13) | ||
|---|---|---|---|---|
| Age, years | 65.6 ± 7.1 | 65.6 ± 8.0 | 65.5 ± 5.7 | 0.95 |
| Male Gender, n (%) | 14 (43.8%) | 7 (36.8%) | 7 (53.8%) | 0.91 |
| BMI, kg/m2 | 30.8 ± 6.5 | 30.4 ± 6.5 | 31.4 ± 6.7 | 0.67 |
| Obesity (BMI ≥ 30kg/m2), n (%) | 17 (53.1%) | 8 (47.4%) | 8 (61.5%) | 0.43 |
| Hemoglobin, mg/dL | 13.6 ± 1.2 | 13.5 ± 1.3 | 13.9 ± 1.1 | 0.29 |
| Platelets, K/uL | 282 ± 62 | 274 ± 52 | 292 ± 75 | 0.44 |
| White Blood Cell Count, K/uL | 7.4 ± 2.6 | 7.4 ± 3.1 | 7.3 ± 1.8 | 0.99 |
| International Normalized Ratio | 1.0 ± 0.1 | 1.0 ± 0.1 | 1.0 ± 0.1 | 0.91 |
| Prothrombin Time, sec | 13.1 ± 0.6 | 13.1 ± 0.7 | 13.1 ± 0.7 | 0.92 |
| aPTT, sec | 31.4 ± 3.7 | 31.0 ± 2.4 | 32.0 ± 5.1 | 0.45 |
| Total knee arthroplasty (TKA), n (%) | 23 (71.9%) | 13 (68.4%) | 10 (76.9%) | 0.70 |
| Unilateral TKA, n (%) | 20 (62.5%) | 13 (68.4%) | 7 (53.8%) | 0.07 |
| Bilateral TKA, n (%) | 3 (9.4%) | 0 (0%) | 3 (100%) | 0.07 |
| Total hip arthroplasty (THA), n (%) | 9 (29.1%) | 6 (31.6%) | 3 (23.1%) | 0.70 |
| Tourniquet time (for TKA), min. | 56.1 ± 12.6 | 55.5 ± 16.0 | 56.9 ± 7.0 | 0.80 |
Central tendency data are reported as mean (±SD) unless otherwise specified (BMI: body mass index; aPTT: activated partial thromboplastin time).
Anticoagulation management and clinical outcomes of the study cohort.
| Value | |
|---|---|
| Duration of OAC, days (median [IQR]) | 19 (13–29) |
| Overall cTTR, (%) | 51% |
| Days to INR > 1.9 (median [IQR]) | 5 (4–8) |
| Post Operative Aspirin Use, n (%) | 4 (12.9%) |
| Any VTE, n (%) | 13 (41.9%) |
| Proximal DVT, n (%) | 3 (9.6%) |
| Unilateral Distal DVT, n (%) | 7 (22.6%) |
| Bilateral Distal DVT, n (%) | 3 (9.6%) |
| Pulmonary Embolism, n (%) | 1 (3.2%) |
| Major Bleeding, n (%) | 0 (0%) |
| Clinically-Relevant Non-Major Bleeding, n (%) | 1 (3.2%) |
| Infection, n (%) | 2 (6.4%) |
| Extended Duration of Warfarin Monotherapy, n (%) | 3 (23.1%) |
| Enoxaparin plus Warfarin, n (%) | 8 (61.5%) |
| Standard Duration of Warfarin Monotherapy, n (%) | 2 (15.4%) |
Central tendency data are reported as mean ± SD unless otherwise specified (cTTR: center-specific time in therapeutic range; INR: international normalized ratio; OAC: oral anticoagulation; ¥patients may have had DVT with or without pulmonary embolism and thus the total number of events may exceed 13).
Figure 1Increased circulating platelet-monocyte aggregates (PMAs) are associated with post-operative VTE.
Circulating PMAs, platelet surface P-selectin expression (P-SEL), and integrin αIIbβ3 activation were measured by whole blood flow cytometry immediately prior to surgery and again 24 hours post-operatively. The number of PMAs, the expression of P-SEL, and integrin αIIbβ3 activation post-operatively was compared to pre-operative (or baseline) values and the fold-change was determined for each patient. (A) Circulating numbers of PMAs were significantly increased post-operatively in patients who developed VTE (+VTE, n = 13), compared to patients without VTE (−VTE, n = 19). In comparison, neither (B) P-SEL expression nor (C) integrin αIIbβ3 activation was associated with VTE. Data show the mean ± SEM for each group.
Figure 2C-reactive protein (CRP) is increased in patients with VTE and correlates with platelet-monocyte aggregates (PMAs).
Plasma was harvested from whole blood collected immediately pre-operatively and again 24 hours post-operatively in all patients. Levels of CRP, d-dimer, and fibrinogen were measured. Shown is the fold-change post-operatively compared to pre-operative (e.g. baseline) levels in each patient. (A) Changes in CRP were significantly higher in patients who developed VTE (+VTE, n = 13), compared to patients without VTE (−VTE, n = 19) and (B) correlated with increased PMAs. In contrast, changes in (C) d-dimer and (D) fibrinogen did not significant differ between patients who developed VTE and those who did not develop VTE. Data show the mean ± SEM for each group. The Pearson’s coefficient (r2) was determined for the correlation between CRP and PMAs.